Natera - NTRA Stock Forecast, Price & News

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.

Natera Price Performance

Shares of Natera stock traded up $1.51 on Monday, reaching $56.68. The company's stock had a trading volume of 1,392,897 shares, compared to its average volume of 1,903,893. The company has a market capitalization of $5.50 billion, a P/E ratio of -9.35 and a beta of 1.33. Natera has a 52-week low of $26.10 and a 52-week high of $129.09. The stock has a 50-day moving average price of $42.21 and a 200-day moving average price of $44.79. The company has a quick ratio of 3.46, a current ratio of 3.58 and a debt-to-equity ratio of 0.63.

Natera (NASDAQ:NTRA - Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The medical research company reported ($1.50) EPS for the quarter, missing analysts' consensus estimates of ($1.47) by ($0.03). Natera had a negative net margin of 79.57% and a negative return on equity of 95.97%. The business had revenue of $198.20 million during the quarter, compared to analysts' expectations of $193.67 million. During the same quarter last year, the firm earned ($1.32) earnings per share. The firm's quarterly revenue was up 39.6% compared to the same quarter last year. Analysts expect that Natera will post -5.73 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Stephens assumed coverage on Natera in a research report on Monday, April 25th. They set an "overweight" rating and a $54.00 price target for the company. Cowen reduced their price target on Natera from $110.00 to $100.00 in a research report on Friday, May 6th. JPMorgan Chase & Co. lifted their price target on Natera from $80.00 to $100.00 in a research report on Friday, August 5th. BTIG Research lifted their price target on Natera to $95.00 in a research report on Monday. Finally, The Goldman Sachs Group reduced their price target on Natera from $90.00 to $80.00 and set a "buy" rating for the company in a research report on Tuesday, April 19th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat, Natera has an average rating of "Moderate Buy" and an average price target of $92.73.

Insider Buying and Selling

In related news, insider Daniel Rabinowitz sold 689 shares of the business's stock in a transaction that occurred on Tuesday, June 28th. The stock was sold at an average price of $39.02, for a total transaction of $26,884.78. Following the completion of the sale, the insider now directly owns 144,478 shares in the company, valued at $5,637,531.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Steven Leonard Chapman sold 1,652 shares of the business's stock in a transaction that occurred on Thursday, June 23rd. The stock was sold at an average price of $35.76, for a total transaction of $59,075.52. Following the completion of the sale, the chief executive officer now directly owns 64,777 shares in the company, valued at $2,316,425.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Daniel Rabinowitz sold 689 shares of the business's stock in a transaction that occurred on Tuesday, June 28th. The stock was sold at an average price of $39.02, for a total value of $26,884.78. Following the sale, the insider now owns 144,478 shares of the company's stock, valued at $5,637,531.56. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,966 shares of company stock worth $550,755. 10.27% of the stock is owned by corporate insiders.